Literature DB >> 832654

Influence of acute renal failure on the protein binding of drugs in animals and in man.

F M Belpaire, M G Bogaert, M M Mussche.   

Abstract

Serum protein binding of phenylbutazone has been measured in the rat, guinea pig, cat, rabbit and dog, and the influence on it of renal failure induced by uranyl nitrate injection has been studied. In all speciies a clearcut decrease in binding was observed after the occurrence of renal failure; the time course of the fall in binding correlated well with development of renal failure. In further experiments, serum protein binding of two acidic drugs (phenylbutazone, warfarin), two basic drugs (papaverine, quinidine) and one neutral drug (digitoxin) was studied in rabbits with experimental renal failure, and the results compared with those obtained in patients with acute renal failure. In the rabbits, a decrease in the binding of phenylbutazone, warfarin, papaverine and quinidine was found, whereas protein binding of digitoxin was unchanged. In man, there was a definite fall in protein binding of phenylbutazone and digitoxin, a small decrease for warfarin and papaverine, and a slight increase for quinidine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832654     DOI: 10.1007/BF00561784

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Serum binding of quinidine in experimental acute renal failure.

Authors:  F Belpaire; M Bogaert; M De Broe; M Mussche
Journal:  Pharmacology       Date:  1977       Impact factor: 2.547

2.  Plasma binding of thiopental in the nephrectomized rabbit.

Authors:  J D TAYLOR; R K RICHARDS; J C DAVIN; J ASHER
Journal:  J Pharmacol Exp Ther       Date:  1954-09       Impact factor: 4.030

3.  Serum albumin in uremia: a clinical investigation correlated with reversible uremia in dogs.

Authors:  R BAKER
Journal:  J Urol       Date:  1951-02       Impact factor: 7.450

4.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

5.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

6.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

7.  The excretion of 3H-papaverine in the rat.

Authors:  F M Belpaire; M G Bogaert
Journal:  Biochem Pharmacol       Date:  1973-01-01       Impact factor: 5.858

8.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

9.  Digitoxin kinetics in patients with impaired renal function.

Authors:  K Rasmussen; J Jervell; L Storstein; K Gjerdrum
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

10.  Increased binding of quinidine to serum albumin and lipoproteins in anuric rats.

Authors:  O G Nilsen; D Fremstad; S Jacobsen
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

View more
  17 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

Review 3.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 6.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

8.  Decreased plasma protein binding of o-methyl red, methyl orange and phenytoin (diphenylhydantoin) in rats wtih acute renal failure [proceedings].

Authors:  C J Bowmer; W E Lindup
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

Review 9.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.